Revance Therapeutics Inc (RVNC)
3.115
-1.18
(-27.39%)
USD |
NASDAQ |
May 10, 11:01
Revance Therapeutics Gross Profit Margin (Quarterly): 74.97% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 74.97% |
| September 30, 2023 | 65.81% |
| June 30, 2023 | 63.35% |
| March 31, 2023 | 67.22% |
| December 31, 2022 | 52.90% |
| September 30, 2022 | 63.00% |
| June 30, 2022 | 66.43% |
| March 31, 2022 | 68.75% |
| Date | Value |
|---|---|
| December 31, 2021 | 69.63% |
| September 30, 2021 | 70.19% |
| June 30, 2021 | 71.14% |
| March 31, 2021 | 68.29% |
| December 31, 2020 | 67.10% |
| September 30, 2020 | 71.71% |
| June 30, 2020 | 92.98% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
52.90%
Minimum
Dec 2022
92.98%
Maximum
Jun 2020
68.90%
Average
68.29%
Median
Mar 2021
Gross Profit Margin (Quarterly) Benchmarks
| AbbVie Inc | 66.74% |
| Alnylam Pharmaceuticals Inc | 86.65% |
| Ionis Pharmaceuticals Inc | 98.20% |
| Madrigal Pharmaceuticals Inc | -- |
| Vertex Pharmaceuticals Inc | 87.27% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -59.15% |
| Return on Invested Capital | -92.45% |
| Profit Margin (Quarterly) | -79.80% |
| Operating Margin (Quarterly) | -76.54% |
| Return on Net Operating Assets | -159.7% |